Fresenius Medical Care (NYSE:FMS) Reaches New 52-Week High – Here’s Why

Fresenius Medical Care AG (NYSE:FMS)’s stock price reached a new 52-week high on Friday . The stock traded as high as $24.35 and last traded at $24.25, with a volume of 248560 shares changing hands. The stock had previously closed at $23.17.

Analyst Ratings Changes

A number of research firms have recently issued reports on FMS. Bank of America raised shares of Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research report on Monday, December 2nd. Truist Financial lifted their target price on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the company a “hold” rating in a research note on Monday, January 6th. Berenberg Bank began coverage on shares of Fresenius Medical Care in a research note on Wednesday, November 6th. They issued a “buy” rating and a $25.60 price target on the stock. Finally, StockNews.com began coverage on Fresenius Medical Care in a research report on Friday, January 3rd. They set a “strong-buy” rating for the company.

Fresenius Medical Care Price Performance

The company has a market capitalization of $14.23 billion, a P/E ratio of 20.04, a P/E/G ratio of 0.75 and a beta of 0.92. The company’s 50-day simple moving average is $22.82 and its 200 day simple moving average is $20.98. The company has a quick ratio of 1.02, a current ratio of 1.37 and a debt-to-equity ratio of 0.42.

Fresenius Medical Care (NYSE:FMS) last issued its quarterly earnings data on Tuesday, November 5th. The company reported $0.45 earnings per share for the quarter, topping analysts’ consensus estimates of $0.42 by $0.03. Fresenius Medical Care had a net margin of 3.43% and a return on equity of 6.04%. The business had revenue of $5.23 billion during the quarter, compared to analysts’ expectations of $5.36 billion. During the same period in the previous year, the company earned $0.31 earnings per share. As a group, sell-side analysts expect that Fresenius Medical Care AG will post 1.53 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Fresenius Medical Care

Several hedge funds have recently modified their holdings of the business. Allworth Financial LP raised its stake in Fresenius Medical Care by 53.1% during the 3rd quarter. Allworth Financial LP now owns 1,675 shares of the company’s stock valued at $36,000 after purchasing an additional 581 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of Fresenius Medical Care during the third quarter valued at about $38,000. GAMMA Investing LLC lifted its stake in shares of Fresenius Medical Care by 50.4% in the third quarter. GAMMA Investing LLC now owns 4,998 shares of the company’s stock valued at $106,000 after buying an additional 1,675 shares during the period. ORG Wealth Partners LLC acquired a new stake in Fresenius Medical Care during the third quarter worth about $112,000. Finally, Venturi Wealth Management LLC increased its stake in Fresenius Medical Care by 1,045.8% during the third quarter. Venturi Wealth Management LLC now owns 5,259 shares of the company’s stock valued at $112,000 after acquiring an additional 4,800 shares during the period. 8.37% of the stock is owned by institutional investors.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.